BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 2005;6:835-847. [PMID: 16296946 DOI: 10.2217/14622416.6.8.835] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Paré L, Altés A, Cajal TRY, Del Rio E, Alonso C, Sedano L, Barnadas A, Baiget M. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. Anti-Cancer Drugs 2007;18:821-5. [DOI: 10.1097/cad.0b013e3280b10d23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
2 Scartozzi M, Maccaroni E, Giampieri R, Pistelli M, Bittoni A, Del Prete M, Berardi R, Cascinu S. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011;12:251-265. [PMID: 21332317 DOI: 10.2217/pgs.10.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
3 Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, Lee SC, Liu JJ, Choo TB, Tham LS, Lee HS, Goh BC, Soong R. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63:121-7. [PMID: 18538445 DOI: 10.1016/j.lungcan.2008.04.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
4 Kristensen M, Pedersen P, Melsen G, Ellehauge J, Mejer J. Variants in the Dihydropyrimidine Dehydrogenase, Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genes Predict Early Toxicity of 5-Fluorouracil in Colorectal Cancer Patients. J Int Med Res 2010;38:870-83. [DOI: 10.1177/147323001003800313] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
5 Cho H, Park YS, Kang WK, Kim J, Lee S. Thymidylate Synthase (TYMS) and Dihydropyrimidine Dehydrogenase (DPYD) Polymorphisms in the Korean Population for Prediction of 5-Fluorouracil-Associated Toxicity. Therapeutic Drug Monitoring 2007;29:190-6. [DOI: 10.1097/ftd.0b013e318040b1fe] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
6 Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10:931-944. [PMID: 19530960 DOI: 10.2217/pgs.09.28] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]
7 Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008;19:915-919. [PMID: 18245778 DOI: 10.1093/annonc/mdm599] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 7.4] [Reference Citation Analysis]
8 Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010;103:845-851. [PMID: 20700125 DOI: 10.1038/sj.bjc.6605831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
9 Avan A, Narayan R, Giovannetti E, Peters GJ. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol 2016; 7(5): 352-369 [PMID: 27777878 DOI: 10.5306/wjco.v7.i5.352] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
10 Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L. Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets Ther 2013;6:811-8. [PMID: 23861589 DOI: 10.2147/OTT.S46498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Kim KW, Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Roh MH, Kim MC, Kim KH, Kim YH, Roh YH, Jeong JS, Kim HJ. Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy. Mol Clin Oncol 2013;1:987-94. [PMID: 24649282 DOI: 10.3892/mco.2013.166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
12 Miyamoto Y, Sakamoto Y, Yoshida N, Baba H. Efficacy of S-1 in colorectal cancer. Expert Opin Pharmacother 2014;15:1761-70. [PMID: 25032886 DOI: 10.1517/14656566.2014.937706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
13 Tripathy D. Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials. The Oncologist 2007;12:375-89. [DOI: 10.1634/theoncologist.12-4-375] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
14 Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138. [PMID: 18299612 DOI: 10.1200/jco.2006.10.4182] [Cited by in Crossref: 277] [Cited by in F6Publishing: 95] [Article Influence: 21.3] [Reference Citation Analysis]
15 Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. Pharmacogenomics 2015;16:1367-77. [DOI: 10.2217/pgs.15.81] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Kirchheiner J, Schwab M. HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. Pharmacology and Therapeutics. Elsevier; 2009. pp. 225-38. [DOI: 10.1016/b978-1-4160-3291-5.50020-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Büchel B, Rhyn P, Schürch S, Bühr C, Amstutz U, Largiadèr CR. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. Biomed Chromatogr 2013;27:7-16. [PMID: 22454320 DOI: 10.1002/bmc.2741] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
18 Ao L, Li L, Sun H, Chen H, Li Y, Huang H, Wang X, Guo Z, Zhou R. Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas. BMC Gastroenterol 2020;20:233. [PMID: 32689938 DOI: 10.1186/s12876-020-01383-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol. 2008;13:498-503. [PMID: 19093176 DOI: 10.1007/s10147-008-0854-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
20 Fouad MA, Salem SE, Hussein MM, Zekri ARN, Hafez HF, El Desouky ED, Shouman SA. Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients. Front Pharmacol 2018;9:1173. [PMID: 30405408 DOI: 10.3389/fphar.2018.01173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]